Strides Arcolab

This page shows the latest Strides Arcolab news and features for those working in and with pharma, biotech and healthcare.

India turns down patent on Gilead's Sovaldi

Cipla, Cadila Healthcare, Hetero, Strides Arcolab, Ranbaxy, Sequent Scientific and Mylan) at a 7% royalty rate.

Sovaldi deal for developing world ‘falls short’

Strides Arcolab - include some of the world's largest generic players, reports the Pharmalot blog.
Pfizer inks $360m deal to buy InnoPharma

Last year, generics giant Mylan made a big leap forward in the sector with a $1.6bn agreement to buy Strides Arcolab's sterile injectables unit Agila, while Becton Dickinson has
Hikma to retain injectables unit

Hikma said in March it decided to look into the future of the division after being sent unsolicited offers in the wake of Mylan's $1.6bn deal to acquire Strides ... Arcolab's injectables unit.
Injectables land-grab set to continue as Hikma reports offers

Hikma has said it is looking into the future of its injectable drugs unit after overtures from possible buyers, just days after Mylan agreed a $1.6bn deal to buy Strides ... Mylan said when it announced its deal for Strides Arcolab's Agila unit that it
Mylan agrees $1.6bn deal to buy Agila injectables unit

Generics firm becomes “top three player” in injectables. Consolidation continues apace in the generics sector, with Mylan agreeing a $1.6bn deal to acquire Strides Arcolab of India's sterile injectables

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Pharma deals in May 2015

360. Aspen/ Strides Arcolab. Divestment. Range of branded and generic drugs.
Deal Watch table for September 2014

200. Shasun / Strides Arcolab. Company acquisition. Shasun is an Indian API and generic company.
Pharma deals during September 2014

year. In India this month, Strides Arcolab has acquired another Indian generic and API supplier Shasun in an all stock deal worth $200m to add products to its portfolio.
The rise of chronic disease in BRIC markets

with Strides Arcolab to jointly manufacture and distribute generic cancer drugs in developing markets.
Pharma deals during February 2013

Geographic expansion and consolidation. Mylan, the generics giant, has announced a trio of deals with Indian companies this month. In the largest, it announced its planned acquisition of Strides Arcolab's

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Add my company

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...